FDA Emergency Use Authorization For Bioterror Drugs Includes HHS Consultation
Executive Summary
FDA will consult with an HHS panel when making decisions on which drug candidates could be authorized for emergency use
You may also be interested in...
“BioShield” Law Nears Passage; FDA Proposes “Pre-Pre-IND” Meetings
FDA counterterrorism regulations will likely face added scrutiny following the expected enactment of Project BioShield, which allows for wider use of investigational products in emergency situations
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials